Ysios Capital Partners names Marc Casellas as Chief Financial Officer
Ysios, the venture capital fund specialized in biotechnology, has created this position to manage the increased activity expected as the initial capital subscription of its first fund, Ysios BioFund I, draws to a close

Barcelona, July 9, 2008 – Ysios Capital Partners, a venture capital firm specialized in biotech investments, has named Marc Casellas Chief Financial Officer. The incorporation of Casellas to Ysios’ team comes along with the imminent constitution of Ysios’ first investment vehicle, the largest biotech venture capital firm in Spain, with a capital of about EUR 60 million in its first closing.

Casellas will be in charge of the administrative management and financial control of the venture capital firm and the fund, and the development of information systems. The new CFO will also establish financial control and monitoring systems with regards to Ysios’ portfolio companies so that Ysios managers have the necessary economic and financial information to make timely decisions and ensure the successful development of these companies.

Casellas comes from Venture Capital industry. Previously, he held a similar position in BCN Ventures SGECR, where he contributed to the design and structuring of a venture capital fund focused on biotechnology and Life Sciences industries. Within BCN Ventures he was actively involved in the development and control of investments in biotechnology, telecom and computer engineering industries.

Previous to BCN Ventures, Casellas was responsible for a number of tasks within the departments of Finance and Information Technology at Danone Group. Further, he has relevant experience as business and IT consultant gained at Price Waterhouse Coopers. Prior to this he worked in the investment funds industry within Caixa Catalunya Group.

Casellas has a Degree in Economics and Business Administration from the University of Navarra, Spain, and holds a Master´s Degree in Financial Management from E.A.E. – U.P.C. (Universitat Politècnica de Catalunya) in Barcelona.

Ysios’ origins
Ysios Capital Partners arose as a result of the efforts of a team of experts from the venture capital and Pharma industries, and biotech start-ups: Joël Jean-Mairet, former CEO of GLYCART Biotechnology AG, Julia Salaverría, former fund manager of Talde, and Josep Lluís Sanfeliu, former Corporate Finance and Business Development executive of Almirall.

ysiosdev

See Full Bio